标题
Targeting angiogenesis in oncology, ophthalmology and beyond
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 22, Issue 6, Pages 476-495
出版商
Springer Science and Business Media LLC
发表日期
2023-04-11
DOI
10.1038/s41573-023-00671-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both?
- (2022) Hellmut G. Augustin et al. CANCER RESEARCH
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- (2022) Jeffrey S Heier et al. LANCET
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- (2022) Charles C Wykoff et al. LANCET
- Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
- (2022) Niharika B. Mettu et al. JAMA Network Open
- Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis® (Ranibizumab) Biosimilar
- (2022) Eunji Kim et al. Ophthalmology and Therapy
- INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA
- (2022) David M. Brown et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
- (2022) Colin S Tan et al. Clinical Ophthalmology
- Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
- (2022) Sonia A. Patel et al. CLINICAL CANCER RESEARCH
- TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2022) Kristina W. Thiel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cellular senescence and senolytics: the path to the clinic
- (2022) Selim Chaib et al. NATURE MEDICINE
- Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
- (2022) Tao Ouyang et al. Frontiers in Oncology
- Dostarlimab: A Review
- (2022) Bárbara Costa et al. Biomolecules
- Endothelial cell diversity: the many facets of the crystal
- (2022) Lorena Perez‐Gutierrez et al. FEBS Journal
- Faricimab: an investigational agent targeting the Tie-2/Angiopoietin pathway and VEGF-A for the treatment of retinal diseases
- (2021) Massimo Nicolò et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition
- (2021) Sergio Crespo-Garcia et al. Cell Metabolism
- Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma
- (2021) Andrew J Armstrong et al. CLINICAL CANCER RESEARCH
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of Notch ligand, Delta-like ligand 4 (DLL4), in cancer angiogenesis—implications for therapy
- (2021) Marlena Brzozowa-Zasada European Surgery-Acta Chirurgica Austriaca
- Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
- (2021) Claire M. Gelfman et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
- (2021) Toni K. Choueiri et al. NATURE MEDICINE
- Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
- (2021) Josh O. Wallsh et al. Cells
- Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer
- (2021) Kabir A Khan et al. EMBO Molecular Medicine
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
- (2021) Mark A. Socinski et al. Journal of Thoracic Oncology
- A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors
- (2021) Amit M. Oza et al. ONCOLOGIST
- Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
- (2021) Rehan M Hussain et al. Drug Design Development and Therapy
- VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
- (2021) Evripidis Lanitis et al. Journal for ImmunoTherapy of Cancer
- An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
- (2021) Yukari Shirai et al. Cancers
- Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
- (2021) Andrew B. Nixon et al. CLINICAL CANCER RESEARCH
- Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
- (2021) Andrew B. Nixon et al. CLINICAL CANCER RESEARCH
- Belzutifan: First Approval
- (2021) Emma D. Deeks DRUGS
- LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy
- (2021) Pin Li et al. EMBO Molecular Medicine
- Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration
- (2021) Arshad M. Khanani et al. JAMA Ophthalmology
- Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study
- (2021) Victor H. Gonzalez et al. Translational Vision Science & Technology
- 354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
- (2021) Vicky Makker et al. Journal for ImmunoTherapy of Cancer
- FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
- (2021) Angela Damato et al. Frontiers in Oncology
- Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- (2021) Nancy M. Holekamp et al. OPHTHALMOLOGY
- Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
- (2020) Angeles Alvarez Secord et al. CLINICAL CANCER RESEARCH
- Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
- (2020) John D. Martin et al. Nature Reviews Clinical Oncology
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
- (2020) Sumanta K. Pal et al. BJU INTERNATIONAL
- Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema
- (2020) Lincoln T. Shaw et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy
- (2020) Irene Tom et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design
- (2020) Kaitlyn Sadtler et al. ADVANCED DRUG DELIVERY REVIEWS
- APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration
- (2020) Michael N. Cohen et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
- (2020) Robert P. Finger et al. BMC Ophthalmology
- FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy
- (2020) Jae Hong Im et al. Nature Communications
- TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma
- (2020) Laurence Albiges et al. ANNALS OF ONCOLOGY
- Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- (2020) Won Suk Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer
- (2020) Yoshiro Itatani et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways
- (2020) Cuiling Zhong et al. Nature Communications
- Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer
- (2020) Ye Zeng et al. Frontiers in Cell and Developmental Biology
- Long-acting intraocular delivery strategies for biological therapy of age-related macular degeneration
- (2019) Shwetha Iyer et al. JOURNAL OF CONTROLLED RELEASE
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adeno-associated virus vector as a platform for gene therapy delivery
- (2019) Dan Wang et al. NATURE REVIEWS DRUG DISCOVERY
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- The Placental Growth Factor Pathway and Its Potential Role in Macular Degenerative Disease
- (2019) Fiona Cunningham et al. CURRENT EYE RESEARCH
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
- (2019) Pravin U. Dugel et al. OPHTHALMOLOGY
- Adipocyte and lipid metabolism in cancer drug resistance
- (2019) Yihai Cao JOURNAL OF CLINICAL INVESTIGATION
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- (2019) Laurence Albiges et al. EUROPEAN UROLOGY
- Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
- (2019) Elad Moisseiev et al. EYE
- The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
- (2019) Johanna C. Bendell et al. ONCOLOGIST
- The tumor vasculature an attractive CAR T cell target in solid tumors
- (2019) Parvin Akbari et al. ANGIOGENESIS
- Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources
- (2019) Vincent Daien et al. BMC Ophthalmology
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
- (2018) Hideki Iwamoto et al. Cell Metabolism
- Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
- (2018) Yoshiro Itatani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning
- (2018) Takahiro Seki et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration
- (2018) Yuanyuan Liu et al. MOLECULAR THERAPY
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Cell Metabolism
- (2018) Guy Eelen et al. PHYSIOLOGICAL REVIEWS
- Choriocapillaris Loss in Advanced Age-Related Macular Degeneration
- (2018) Carlos A. Moreira-Neto et al. Journal of Ophthalmology
- Anti-Angiogenics: Current Situation and Future Perspectives
- (2018) Katja Zirlik et al. Oncology Research and Treatment
- Progression of Geographic Atrophy in Age-related Macular Degeneration
- (2018) Tiarnan D. Keenan et al. OPHTHALMOLOGY
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial
- (2017) Sobha Sivaprasad et al. LANCET
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Therapeutic targeting of the angiopoietin–TIE pathway
- (2017) Pipsa Saharinen et al. NATURE REVIEWS DRUG DISCOVERY
- Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology
- (2017) Hellmut G. Augustin et al. SCIENCE
- A miR-327–FGF10–FGFR2-mediated autocrine signaling mechanism controls white fat browning
- (2017) Carina Fischer et al. Nature Communications
- Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors
- (2017) Szilvia Torok et al. Theranostics
- Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
- (2017) Filipe Mira et al. Journal of Ophthalmology
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications
- (2017) Evan N. Dunn et al. Ophthalmic Surgery Lasers & Imaging Retina
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
- (2016) Sophia Frentzas et al. NATURE MEDICINE
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
- (2016) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
- (2016) Maureen G. Maguire et al. OPHTHALMOLOGY
- Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
- (2016) Yin Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat
- (2016) Takahiro Seki et al. Nature Communications
- Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
- (2016) Yunlong Yang et al. Nature Communications
- Defining response to anti-VEGF therapies in neovascular AMD
- (2015) W M Amoaku et al. EYE
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants
- (2015) Lars G Fritsche et al. NATURE GENETICS
- Treatment Choice for Diabetic Macular Edema
- (2015) Daniel F. Martin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2015) David M. Brown et al. OPHTHALMOLOGY
- Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion
- (2015) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Molecular pathogenesis of retinal and choroidal vascular diseases
- (2015) Peter A. Campochiaro PROGRESS IN RETINAL AND EYE RESEARCH
- Immune mechanisms in inflammatory and degenerative eye disease
- (2015) Victor L. Perez et al. TRENDS IN IMMUNOLOGY
- Endothelial destabilization by angiopoietin-2 via integrin β1 activation
- (2015) Laura Hakanpaa et al. Nature Communications
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
- (2014) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
- (2014) D. C. Smith et al. CLINICAL CANCER RESEARCH
- A review of anti-VEGF agents for proliferative diabetic retinopathy
- (2014) P Osaadon et al. EYE
- Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
- (2014) S. Ramakrishnan et al. Journal of Neuroimmune Pharmacology
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
- (2014) Yihai Cao Nature Reviews Endocrinology
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
- (2014) K M Dodd et al. ONCOGENE
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2014) Jean-François Korobelnik et al. OPHTHALMOLOGY
- Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues
- (2014) J. Honek et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study
- (2013) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Angiogenesis and Vascular Functions in Modulation of Obesity, Adipose Metabolism, and Insulin Sensitivity
- (2013) Yihai Cao Cell Metabolism
- Adipose Vascular Endothelial Growth Factor Regulates Metabolic Homeostasis through Angiogenesis
- (2013) Hoon-Ki Sung et al. Cell Metabolism
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
- (2013) David M. Brown et al. OPHTHALMOLOGY
- Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
- (2013) Y. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment
- (2013) V. T. Phan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
- (2013) Krastan B. Blagoev et al. Cell Reports
- Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment
- (2013) Hala Ahmadieh et al. Biomed Research International
- Aging, Cellular Senescence, and Cancer
- (2012) Judith Campisi Annual Review of Physiology
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Ziv-aflibercept: binding to more than VEGF-A—does more matter?
- (2012) Jeffrey M. Clarke et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Diabetic Retinopathy
- (2012) David A. Antonetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Vision-Related Function after Ranibizumab for Macular Edema after Retinal Vein Occlusion
- (2012) Rohit Varma et al. OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs
- (2012) E.-M. E. Hedlund et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic Angiogenesis for Treating Cardiovascular Diseases
- (2012) Lorenzo Deveza et al. Theranostics
- Elevated membrane attack complex in human choroid with high risk complement factor H genotypes
- (2011) Robert F. Mullins et al. EXPERIMENTAL EYE RESEARCH
- The burden of disease of retinal vein occlusion: review of the literature
- (2011) M Laouri et al. EYE
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
- (2011) James Finke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
- (2011) Seth B. Coffelt et al. JOURNAL OF IMMUNOLOGY
- Thyroid Dysfunction from Antineoplastic Agents
- (2011) O.-P. R. Hamnvik et al. JNCI-Journal of the National Cancer Institute
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RESTORE Study
- (2011) Paul Mitchell et al. OPHTHALMOLOGY
- Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice
- (2011) A. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Forty-Year Journey of Angiogenesis Translational Research
- (2011) Y. Cao et al. Science Translational Medicine
- PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
- (2010) Carlos Bais et al. CELL
- Lymphangiogenesis: Molecular Mechanisms and Future Promise
- (2010) Tuomas Tammela et al. CELL
- Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate–resistant patients: recommendations and evidence
- (2010) J. Younus et al. Current Oncology
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic DLL4 blockade induces vascular neoplasms
- (2010) Minhong Yan et al. NATURE
- Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy
- (2010) Napoleone Ferrara NATURE MEDICINE
- Off-tumor target—beneficial site for antiangiogenic cancer therapy?
- (2010) Yihai Cao Nature Reviews Clinical Oncology
- Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
- (2010) Yihai Cao NATURE REVIEWS DRUG DISCOVERY
- Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
- (2010) David M. Brown et al. OPHTHALMOLOGY
- Optimizing the Delivery of Cancer Drugs That Block Angiogenesis
- (2010) Y. Cao et al. Science Translational Medicine
- Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6
- (2010) YOSHIKO AOYAGI et al. Oncology Letters
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- Why are tumour blood vessels abnormal and why is it important to know?
- (2009) J A Nagy et al. BRITISH JOURNAL OF CANCER
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
- (2009) Johannes Lammer et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Hypoxia-Independent Angiogenesis in Adipose Tissues during Cold Acclimation
- (2009) Yuan Xue et al. Cell Metabolism
- Tumor angiogenesis and molecular targets for therapy
- (2009) Yihai Cao Frontiers in Bioscience-Landmark
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature
- (2009) E.-M. Hedlund et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
- (2009) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
- (2009) Y. Cao Science Signaling
- VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis
- (2008) G Thurston et al. BRITISH JOURNAL OF CANCER
- Molecular and developmental biology of the hemangioblast
- (2008) Jing-Wei Xiong DEVELOPMENTAL DYNAMICS
- Imaging of the hypoxia-inducible factor pathway: insights into oxygen sensing
- (2008) U. Berchner-Pfannschmidt et al. EUROPEAN RESPIRATORY JOURNAL
- Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
- (2008) Tuomas Tammela et al. NATURE
- HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
- (2008) Zoltan Arany et al. NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome
- (2008) Y. Xue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
- (2008) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- White Fat Progenitor Cells Reside in the Adipose Vasculature
- (2008) W. Tang et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started